Aline Frossard Ribeiro Bortoluzzi

Aline Frossard Ribeiro Bortoluzzi

Auto-generated profile, based on publicly available information

Aline Frossard Ribeiro Bortoluzzi

Universidade de São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2026 in Epidemiologia e Serviços de Saúde
Verified
Journal Article
Open access
Patricia SoarezPatricia Soarez
Patricia Soarez
ESErica Aranha Suzumura
Erica Aranha Suzumura
ABAline Frossard Ribeiro Bortoluzzi
Aline Frossard Ribeiro Bortoluzzi
ANAna Carolina Nonato
Ana Carolina Nonato
FMFernando Henrique de Albuquerque Maia
Fernando Henrique de Albuquerque Maia
Uwe SiebertUwe Siebert
Uwe Siebert

1 January 2026 in Epidemiologia e Serviços de Saúde
Verified
Journal Article
Open access
ANAna Carolina Nonato
Ana Carolina Nonato
ESErica Aranha Suzumura
Erica Aranha Suzumura
BABruna de Oliveira Ascef
Bruna de Oliveira Ascef
ABAline Frossard Ribeiro Bortoluzzi
Aline Frossard Ribeiro Bortoluzzi
FMFernando Henrique de Albuquerque Maia
Fernando Henrique de Albuquerque Maia
Patricia SoarezPatricia Soarez
Patricia Soarez

1 January 2026 in Epidemiologia e Serviços de Saúde
Verified
Journal Article
Open access
Patricia SoarezPatricia Soarez
Patricia Soarez
ESErica Aranha Suzumura
Erica Aranha Suzumura
ABAline Frossard Ribeiro Bortoluzzi
Aline Frossard Ribeiro Bortoluzzi
ANAna Carolina Nonato
Ana Carolina Nonato
FMFernando Henrique de Albuquerque Maia
Fernando Henrique de Albuquerque Maia
Uwe SiebertUwe Siebert
Uwe Siebert

1 January 2026 in Epidemiologia e Serviços de Saúde
Verified
Journal Article
Open access
ANAna Carolina Nonato
Ana Carolina Nonato
ESErica Aranha Suzumura
Erica Aranha Suzumura
BABruna de Oliveira Ascef
Bruna de Oliveira Ascef
ABAline Frossard Ribeiro Bortoluzzi
Aline Frossard Ribeiro Bortoluzzi
FMFernando Henrique de Albuquerque Maia
Fernando Henrique de Albuquerque Maia
Patricia SoarezPatricia Soarez
Patricia Soarez

1 January 2026 in Epidemiologia e Serviços de Saúde
Verified
Journal Article
Open access
Sidney DominguesSidney Domingues
Sidney Domingues
Patricia SoarezPatricia Soarez
Patricia Soarez
ESErica Aranha Suzumura
Erica Aranha Suzumura
ANAna Carolina Nonato
Ana Carolina Nonato
ABAline Frossard Ribeiro Bortoluzzi
Aline Frossard Ribeiro Bortoluzzi
Uwe SiebertUwe Siebert
Uwe Siebert

23 July 2026 in JORNAL DE ASSISTÊNCIA FARMACÊUTICA E FARMACOECONOMIA
Verified
Journal Article
Open access
PDF file
RSRicardo Dos Santos Simões
Ricardo Dos Santos Simões
ABAline Frossard Ribeiro Bortoluzzi
Aline Frossard Ribeiro Bortoluzzi
JMJanaina Cardoso Nunes Marinho
Janaina Cardoso Nunes Marinho
JGJulia Simoes Correa Galendi
Julia Simoes Correa Galendi
Objective: To evaluate the efficacy and safety of ivosidenib as a monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma harboring the IDH1R132 mutation, previously treated with at least one line of systemic therapy. Method: The evidence search was conducted in electronic databases Medline via PubMed, Embase, Cochrane and Lilacs, with a cutoff date of December 2024, to identify randomized clinical trials. Analyzed outcomes included progression-free survival (PFS), overall survival (OS), quality of life, and adverse events. Two investigators performed the search, study selection, data extraction, and assessed quality and risk of bias using the Cochrane RoB2 tool. The certainty of evidence was analyzed with the support of the GRADE tool. Results: Two publications derived from the same pivotal randomized clinical trial, identified as ClarIDHy, were included. The median PFS was 2.7 months in patients treated with ivosidenib, compared to 1.4 months in those who received a placebo (HR = 0.37; 95%CI: 0.25 to 0.54). The six- and 12-month PFS rates were 32% and 22%, respectively. The final OS analysis indicated a benefit of ivosidenib compared to placebo. Overall, the safety profile of ivosidenib was favorable, with nausea, diarrhea, and fatigue being the most commonly reported adverse events in both groups. Conclusion: In patients with locally advanced or metastatic cholangiocarcinoma harboring the IDH1 mutation, ivosidenib emerges as a viable therapeutic option; however, this conclusion should be interpreted with caution, as it is primarily based on two publications derived from a single pivotal clinical trial, which limits the robustness of the available evidence.